In phase 1/2a clinical studies, administration of GalNAc conjugated ASO targeting apolipoprotein C-III (apoC-III) mRNA, showed clear dose dependence, up to 92% reduction in apoC-III protein levels and up to 77% reduction in triglyceride levels, which is very promising for patients with hypertriglyceridaemia or coronary heart disease[62]. Here, APOC3 is linked to hypertriglyceridemia.